Salta al contenuto
VuFind
English
Deutsch
Español
Français
Italiano
日本語
Nederlands
Português
Português (Brasil)
中文(简体)
中文(繁體)
Türkçe
עברית
Gaeilge
Cymraeg
Ελληνικά
Català
Euskara
Русский
Čeština
Suomi
Svenska
polski
Dansk
slovenščina
اللغة العربية
বাংলা
Galego
Tiếng Việt
Hrvatski
हिंदी
Հայերէն
Українська
Sámegiella
Монгол
Lingua
Tutti i Campi
Titolo
Autore
Soggetto
Collocazione
ISBN/ISSN
Tag
Cerca
Avanzata
Future of flu vaccines. Expedi...
Citazione
Invia SMS
Invia email
Stampa
Esporta il record
Esporta a RefWorks
Esporta a EndNoteWeb
Esporta a EndNote
PLink permanente
Future of flu vaccines. Expediting clinical trials in a pandemic.
Mostra altre versioni (1)
Dettagli Bibliografici
Autori principali:
Pollard, A
,
Reiner, A
,
John, T
,
Sheasby, E
,
Snape, M
,
Faust, S
,
Collinson, A
,
Finn, A
,
Heath, P
,
Miller, E
Natura:
Journal article
Lingua:
English
Pubblicazione:
2009
Posseduto
Descrizione
Altre versioni (1)
Documenti analoghi
MARC21
Documenti analoghi
Future of flu vaccines. Expediting clinical trials in a pandemic.
di: Pollard, A, et al.
Pubblicazione: (2009)
Relationships between reactogenicity and age, dose number and immunogenicity in 937 children receiving two doses of ASO3(B)-adjuvanted split virion or whole virus H1N1 influenza A 2009 pandemic vaccines
di: Walker, W, et al.
Pubblicazione: (2011)
Safety and immunogenicity of AS03B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: open label, randomised, parallel group, multicentre study.
di: Waddington, C, et al.
Pubblicazione: (2010)
Safety and immunogenicity of AS03 B adjuvanted split virion versus non-adjuvanted whole virion H1N1 influenza vaccine in UK children aged 6 months-12 years: Open label, randomised, parallel group, multicentre study
di: Waddington, C, et al.
Pubblicazione: (2010)
Open-label, randomised, parallel-group, multicentre study to evaluate the safety, tolerability and immunogenicity of an AS03(B)/oil-in-water emulsion-adjuvanted (AS03(B)) split-virion versus non-adjuvanted whole-virion H1N1 influenza vaccine in UK children 6 months to 12 years of age.
di: Waddington, C, et al.
Pubblicazione: (2010)